EGFR and non-small cell lung carcinoma: Furthermore, several clinical trials have demonstrated the encouraging efficacy and safety of combined anlotinib with EGFR-TKI for previously untreated, EGFR-mutated advanced NSCLC patients (Dingzhi Huang, 2020; D. Zhong, 2020; Chu et al., 2022).